Related Experiment Video

Updated: May 21, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans

Peter J Wild1, Kristian Ikenberg, Thomas J Fuchs

  • 1Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland.

EMBO Molecular Medicine
|June 9, 2012
PubMed

Insights

TP53 gene inactivation and mTORC1 pathway activation are key drivers in aggressive endometrial cancers. These molecular changes, found in both type I and type II subtypes, predict poor patient survival and are crucial for tumor development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Type II endometrial carcinomas are aggressive tumors often linked to TP53 gene inactivation.
  • Understanding the molecular drivers of endometrial cancer subtypes is crucial for developing effective therapies.

Purpose of the Study:

  • To investigate the role of Trp53 deficiency and mTORC1 pathway activation in endometrial tumorigenesis.
  • To analyze the prevalence and prognostic significance of these molecular alterations in human endometrial carcinomas.

Main Methods:

  • Utilized a mouse model with specific deletion of Trp53 in the endometrium.
  • Examined histological changes and developed tumors in the mouse model.
  • Analyzed mTORC1 pathway activation and p53 status in 521 human endometrial carcinoma samples.

Main Results:

  • Trp53 deletion in mice recapitulated human type II endometrial carcinoma precursor lesions and subtypes.
  • mTORC1 pathway activation was frequent in precursor lesions and tumors, indicating genetic cooperation with Trp53 deficiency.
  • mTORC1 pathway activation was observed in both type I and type II endometrial cancer subtypes.
  • Both mTORC1 pathway activation and p53 status independently predicted poor patient survival.

Conclusions:

  • Combined p53 inactivation and mTORC1 pathway activation are unifying pathogenic features in aggressive, late-stage endometrial tumors.
  • These molecular alterations play distinct roles in initiating different endometrial cancer subtypes.
  • Targeting the mTORC1 pathway alongside addressing p53 status may offer therapeutic strategies for aggressive endometrial cancers.

More Related Videos

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice07:44

Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice

Published on: February 17, 2023

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...